CD19-UCART

BIOLOGICAL2 trials

Sponsors

Bioray Laboratories

Conditions

Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia (ALL)Non Hodgkin LymphomaNon Hodgkin Lymphoma (NHL)

Phase 1

Safety and Efficacy Evaluation of Next-generation CD19-UCART

Not yet recruitingNCT05381181

Bioray LaboratoriesAcute Lymphoblastic Leukemia, Non Hodgkin Lymphoma

Start: 2023-12-20End: 2026-05-03Target: 20Updated: 2023-01-27

Unknown Phase

Safety and Efficacy Evaluation of CD19-UCART

SuspendedNCT03229876

Bioray LaboratoriesAcute Lymphoblastic Leukemia (ALL), Non Hodgkin Lymphoma (NHL)

Start: 2019-06-01End: 2023-12-30Target: 20Updated: 2023-07-24

Related Papers

Allogeneic CD19-targeted CAR-T therapy (BRL-301) for relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).

Journal of Clinical Oncology2026-05-28

Global Perspective on the Development of Genetically Modified Immune Cells for Cancer Therapy.

2021-02-156 citations